ITERUM THERAPEUTICS PLC: FDA Suggests Type C Meeting for Proposed Clinical Study of ORLYNVAH
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 13 2026
0mins
Source: moomoo
- FDA Recommendation: The FDA has recommended a type C meeting for a proposed clinical investigation related to Orlyn NVH.
- Purpose of Meeting: The meeting aims to discuss the clinical development plan and address any questions regarding the proposed investigation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
